JP2012532932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532932A5 JP2012532932A5 JP2012520707A JP2012520707A JP2012532932A5 JP 2012532932 A5 JP2012532932 A5 JP 2012532932A5 JP 2012520707 A JP2012520707 A JP 2012520707A JP 2012520707 A JP2012520707 A JP 2012520707A JP 2012532932 A5 JP2012532932 A5 JP 2012532932A5
- Authority
- JP
- Japan
- Prior art keywords
- medium
- botulinum neurotoxin
- fermentation medium
- apf
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002609 medium Substances 0.000 claims 35
- 238000000855 fermentation Methods 0.000 claims 33
- 108030001720 Bontoxilysin Proteins 0.000 claims 32
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 32
- 230000004151 fermentation Effects 0.000 claims 32
- 238000000034 method Methods 0.000 claims 26
- 241000193155 Clostridium botulinum Species 0.000 claims 13
- 239000012501 chromatography medium Substances 0.000 claims 10
- 239000003480 eluent Substances 0.000 claims 9
- 239000001963 growth medium Substances 0.000 claims 8
- 238000004587 chromatography analysis Methods 0.000 claims 6
- 238000001914 filtration Methods 0.000 claims 6
- 238000000746 purification Methods 0.000 claims 5
- 238000005349 anion exchange Methods 0.000 claims 4
- 238000005571 anion exchange chromatography Methods 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 238000005277 cation exchange chromatography Methods 0.000 claims 3
- 238000007865 diluting Methods 0.000 claims 3
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 2
- 238000005341 cation exchange Methods 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 235000021118 plant-derived protein Nutrition 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 108010064851 Plant Proteins Proteins 0.000 claims 1
- 229940041514 candida albicans extract Drugs 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000012138 yeast extract Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/502,181 US8129139B2 (en) | 2009-07-13 | 2009-07-13 | Process for obtaining botulinum neurotoxin |
| US12/502,181 | 2009-07-13 | ||
| PCT/US2010/041745 WO2011008713A1 (en) | 2009-07-13 | 2010-07-12 | Process and system for obtaining botulinum neurotoxin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015214835A Division JP6356651B2 (ja) | 2009-07-13 | 2015-10-30 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532932A JP2012532932A (ja) | 2012-12-20 |
| JP2012532932A5 true JP2012532932A5 (https=) | 2013-08-29 |
| JP5887268B2 JP5887268B2 (ja) | 2016-03-16 |
Family
ID=42537891
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520707A Active JP5887268B2 (ja) | 2009-07-13 | 2010-07-12 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
| JP2015214835A Active JP6356651B2 (ja) | 2009-07-13 | 2015-10-30 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
| JP2016219708A Active JP6704329B2 (ja) | 2009-07-13 | 2016-11-10 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
| JP2020001854A Withdrawn JP2020078306A (ja) | 2009-07-13 | 2020-01-09 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
| JP2021142559A Pending JP2021193103A (ja) | 2009-07-13 | 2021-09-01 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
| JP2024098461A Pending JP2024111147A (ja) | 2009-07-13 | 2024-06-19 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015214835A Active JP6356651B2 (ja) | 2009-07-13 | 2015-10-30 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
| JP2016219708A Active JP6704329B2 (ja) | 2009-07-13 | 2016-11-10 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
| JP2020001854A Withdrawn JP2020078306A (ja) | 2009-07-13 | 2020-01-09 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
| JP2021142559A Pending JP2021193103A (ja) | 2009-07-13 | 2021-09-01 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
| JP2024098461A Pending JP2024111147A (ja) | 2009-07-13 | 2024-06-19 | ボツリヌス神経毒素を得るためのプロセスおよびシステム |
Country Status (18)
| Country | Link |
|---|---|
| US (19) | US8129139B2 (https=) |
| EP (6) | EP3252070B1 (https=) |
| JP (6) | JP5887268B2 (https=) |
| KR (5) | KR101916139B1 (https=) |
| CN (2) | CN106117325B (https=) |
| BR (1) | BR112012000784A2 (https=) |
| CA (1) | CA2767760C (https=) |
| CY (2) | CY1119519T1 (https=) |
| DK (2) | DK3252070T3 (https=) |
| ES (2) | ES2770031T3 (https=) |
| HU (2) | HUE033888T2 (https=) |
| IN (1) | IN2012DN00456A (https=) |
| MX (4) | MX2012000615A (https=) |
| PL (2) | PL3252070T3 (https=) |
| PT (2) | PT2454275T (https=) |
| RU (1) | RU2561459C2 (https=) |
| SI (2) | SI3252070T1 (https=) |
| WO (1) | WO2011008713A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| ES2509872T3 (es) | 2005-03-03 | 2014-10-20 | Allergan, Inc. | Procedimientos para obtener una toxina clostrídica |
| US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| SI2490986T1 (sl) | 2009-10-21 | 2018-12-31 | Revance Therapeutics, Inc. | Metode in sistemi za prečiščenje nekompleksiranega nevrotoksina botulina |
| KR20110046178A (ko) * | 2009-10-28 | 2011-05-04 | 엘지전자 주식회사 | 이동 단말기 |
| KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| US9605887B2 (en) | 2011-07-29 | 2017-03-28 | Hdt Expeditionary Systems, Inc. | Transportable packaged ice supply system for high temperature environments |
| GB201113544D0 (en) * | 2011-08-05 | 2011-09-21 | Fujifilm Diosynth Biotechnologies Uk Ltd | Purification process |
| WO2014197837A1 (en) * | 2013-06-06 | 2014-12-11 | University Of Florida Research Foundation, Inc. | Materials and methods for producing a biological toxin |
| HK1225744A1 (zh) | 2013-07-30 | 2017-09-15 | Merz Pharma Gmbh & Co. Kgaa | 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用 |
| KR101339349B1 (ko) * | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| JP6373376B2 (ja) * | 2013-11-15 | 2018-08-15 | ノバルティス アーゲー | 残留細胞培養不純物の除去 |
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| KR101729251B1 (ko) * | 2015-04-28 | 2017-04-21 | 주식회사 대웅 | 보툴리눔 독소의 제조를 위한 배지 조성물 |
| GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| WO2017161345A1 (en) | 2016-03-18 | 2017-09-21 | Biomadison, Inc. | Improved cell based assay |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| KR102463881B1 (ko) * | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
| EP3600221A4 (en) * | 2017-03-22 | 2021-01-13 | Bonti, Inc. | BOTULINARY NEUROTOXINS FOR USE IN THERAPY |
| CA3060669A1 (en) * | 2017-04-28 | 2018-11-01 | Bonti, Inc. | Botulinum neurotoxins production methods |
| CA3068292A1 (en) * | 2017-06-26 | 2019-01-03 | Bonti, Inc. | Clostridial neurotoxin formulations and use |
| KR102140531B1 (ko) * | 2018-08-07 | 2020-08-04 | (주)휴온스 | Gly-Tβ4의 제조방법 |
| US11926853B2 (en) | 2018-12-21 | 2024-03-12 | The Research Foundation For Microbial Diseases Of Osaka University | Botulinum toxin producing method |
| KR102209159B1 (ko) | 2019-03-29 | 2021-01-29 | (주)제테마 | 독소의 제조방법 |
| KR102197224B1 (ko) | 2019-03-29 | 2020-12-31 | (주)제테마 | 배지 조성물 |
| KR102516203B1 (ko) * | 2019-04-15 | 2023-03-30 | (주)제테마 | 보툴리눔 독소의 제조방법 |
| KR102485146B1 (ko) * | 2019-04-15 | 2023-01-06 | (주)제테마 | 보툴리눔 독소의 제조방법 |
| US10851363B1 (en) | 2019-05-22 | 2020-12-01 | Boke Zhang | Multilayer nano-cell containing biomolecules |
| KR102287437B1 (ko) * | 2019-08-14 | 2021-08-09 | 주식회사 프로톡스 | 보툴리눔 독소의 제조방법 |
| TWI854077B (zh) * | 2019-12-20 | 2024-09-01 | 瑞士商葛德瑪控股公司 | 生產肉毒桿菌毒素的方法 |
| TW202136286A (zh) * | 2019-12-20 | 2021-10-01 | 瑞士商葛德瑪控股公司 | 純化肉毒桿菌毒素的方法 |
| CN114958887B (zh) * | 2021-02-26 | 2024-10-25 | 重庆誉颜制药有限公司 | 一种经修饰的毒素多肽的制备方法 |
| KR102724651B1 (ko) * | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| KR102427362B1 (ko) * | 2021-11-11 | 2022-08-01 | (주)이니바이오 | 보툴리눔 독소 제제의 건조 공정 |
| KR102850152B1 (ko) * | 2022-07-27 | 2025-08-25 | (주)이니바이오 | 감압건조장치 및 이를 이용한 감압건조방법 |
| EP4615489A1 (en) | 2022-11-07 | 2025-09-17 | Allergan, Inc. | Prevention of post-operative atrial fibrillation with a botulinum toxin |
| CH720444A2 (de) | 2023-01-20 | 2024-07-31 | Abbvie Inc | Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten |
| CH720447A2 (de) | 2023-01-20 | 2024-07-31 | Abbvie Inc | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a |
| WO2025111258A1 (en) * | 2023-11-20 | 2025-05-30 | Abbvie Inc. | Clostridium botulinum neurotoxin serotype a compositions and improved filtration processes |
| DE102025101336A1 (de) | 2024-01-19 | 2025-07-24 | Abbvie Inc. | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401683A (en) | 1981-07-06 | 1983-08-30 | Fmc Corporation | Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin |
| WO1994000481A1 (en) | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
| TW257792B (https=) * | 1992-10-01 | 1995-09-21 | Lilly Co Eli | |
| JP3265577B2 (ja) | 1992-10-13 | 2002-03-11 | デューク・ユニバーシティ | アポリポ蛋白ｅの４型イソ型の測定法 |
| US5314822A (en) | 1992-10-15 | 1994-05-24 | Merck & Co., Inc. | Method of clonal growth of Streptococcus pneumoniae |
| US5962637A (en) | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| AU2907695A (en) | 1994-08-08 | 1996-03-07 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
| US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| EP0773788B1 (en) | 1995-06-06 | 2003-05-07 | L. Bruce Pearce | Improved compositions and methods for chemodenervation using neurotoxins |
| US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
| DE69838383T2 (de) | 1997-05-28 | 2008-06-05 | Novartis Vaccines And Diagnostics S.R.L. | Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs |
| JP4055248B2 (ja) * | 1998-05-25 | 2008-03-05 | 味の素株式会社 | 精製ヒトアクチビン及びその製造方法 |
| GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US6558926B1 (en) | 1999-07-16 | 2003-05-06 | Massachusetts Institute Of Technology | Method for production of tetanus toxin using media substantially free of animal products |
| WO2001036655A2 (en) | 1999-11-12 | 2001-05-25 | Eli Lilly And Company | Method for optimization of a medium for glycopeptide fermentation |
| AU1486801A (en) | 1999-11-15 | 2001-05-30 | Curagen Corporation | Novel growth factor polypeptides and nucleic acids encoding same |
| DE10004024A1 (de) | 2000-01-31 | 2001-08-02 | Guenther Bebenroth | Schaltungsanordnung zum Betreiben von Leuchtdioden |
| DK1398038T4 (da) | 2000-02-08 | 2011-03-28 | Allergan Inc | Lægemidler med botulinustoxin |
| US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
| US8632785B2 (en) | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| US6811067B2 (en) | 2000-02-10 | 2004-11-02 | Magna International Inc. | Vehicle tailgate with storage capacity |
| JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| CA2456843A1 (en) | 2001-08-14 | 2003-02-27 | Statens Serum Institut | A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine |
| US7208285B2 (en) | 2001-08-28 | 2007-04-24 | Allergan, Inc. | Fret protease assays for botulinum serotype A/E toxins |
| US8022172B2 (en) | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| KR20030060150A (ko) | 2002-01-07 | 2003-07-16 | (주)메디톡스 | 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법 |
| RU2230325C2 (ru) * | 2002-08-15 | 2004-06-10 | Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации | Способ приготовления очищенного препарата ботулинического токсина типа а |
| US7183066B2 (en) | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
| US20040235139A1 (en) | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
| EP1493478B1 (en) * | 2003-07-02 | 2007-04-04 | Filtertek Inc. | Multiple bridge retainer |
| US7160699B2 (en) | 2003-09-25 | 2007-01-09 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
| US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| US7452697B2 (en) | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
| US20070264373A1 (en) | 2004-01-26 | 2007-11-15 | Ian Carroll | Toxin Induced Sympathectomy |
| ES2374822T3 (es) | 2004-02-24 | 2012-02-22 | Allergan, Inc. | Ensayo de selección de toxinas botul�?nicas. |
| EP2266599B1 (en) | 2004-07-26 | 2014-04-16 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition with a botulinum neurotoxin |
| US20060069562A1 (en) | 2004-09-10 | 2006-03-30 | Adams Marilyn J | Word categories |
| US7399607B2 (en) | 2004-09-22 | 2008-07-15 | Allergan, Inc. | Fluorescence polarization assays for determining clostridial toxin activity |
| US20070258992A1 (en) | 2004-10-06 | 2007-11-08 | Atassi M Zouhair | Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides |
| US20070277577A1 (en) | 2004-10-29 | 2007-12-06 | Allen Clyde G | Sheet metal brake and hinge mechanism therefor |
| EP2360171A1 (en) * | 2004-12-23 | 2011-08-24 | Novo Nordisk Health Care AG | Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest |
| ES2509872T3 (es) | 2005-03-03 | 2014-10-20 | Allergan, Inc. | Procedimientos para obtener una toxina clostrídica |
| EP2293064B1 (en) | 2005-04-05 | 2012-04-04 | Allergan, Inc. | Lipophilic dye-based FRET assays for clostridial toxin activity |
| US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| US7744904B1 (en) | 2005-09-26 | 2010-06-29 | B.B. Scientific L.L.C. | Stabilization of Clostridium botulinum neurotoxin complex |
| CN103126971A (zh) | 2005-11-17 | 2013-06-05 | 雷文斯治疗公司 | 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法 |
| PT2271670E (pt) | 2008-03-14 | 2014-11-28 | Allergan Inc | Ensaio imunobaseado da atividade do serotipo a da toxina botulínica |
| KR20090120222A (ko) | 2008-05-19 | 2009-11-24 | (주)메디톡스 | 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법 |
| KR101923847B1 (ko) | 2009-03-13 | 2018-11-29 | 알러간, 인코포레이티드 | 면역 기반 재표적화된 엔도펩티다제 활성 검정 |
| US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| SI2490986T1 (sl) | 2009-10-21 | 2018-12-31 | Revance Therapeutics, Inc. | Metode in sistemi za prečiščenje nekompleksiranega nevrotoksina botulina |
| NL2010545C2 (en) | 2013-03-28 | 2014-09-30 | Ihc Holland Ie Bv | Skidding system for an offshore installation or vessel. |
| KR101339349B1 (ko) | 2013-08-02 | 2013-12-09 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| US9889608B2 (en) | 2014-11-10 | 2018-02-13 | International Business Machines Corporation | Matching the scale of independent objects or intelligently scaling objects when 3D printing |
| KR101723167B1 (ko) | 2015-04-28 | 2017-04-05 | 주식회사 대웅 | 보툴리눔 독소의 제조를 위한 배지 조성물 |
| KR101775682B1 (ko) | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
| KR102463881B1 (ko) | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
-
2009
- 2009-07-13 US US12/502,181 patent/US8129139B2/en active Active
-
2010
- 2010-07-12 KR KR1020177003936A patent/KR101916139B1/ko active Active
- 2010-07-12 PL PL17180720T patent/PL3252070T3/pl unknown
- 2010-07-12 CA CA2767760A patent/CA2767760C/en active Active
- 2010-07-12 WO PCT/US2010/041745 patent/WO2011008713A1/en not_active Ceased
- 2010-07-12 ES ES17180720T patent/ES2770031T3/es active Active
- 2010-07-12 EP EP17180720.9A patent/EP3252070B1/en active Active
- 2010-07-12 KR KR1020127003603A patent/KR101784532B1/ko active Active
- 2010-07-12 SI SI201031966T patent/SI3252070T1/sl unknown
- 2010-07-12 KR KR1020187031605A patent/KR20180122039A/ko not_active Ceased
- 2010-07-12 HU HUE10733117A patent/HUE033888T2/en unknown
- 2010-07-12 PT PT107331175T patent/PT2454275T/pt unknown
- 2010-07-12 DK DK17180720.9T patent/DK3252070T3/da active
- 2010-07-12 EP EP19200775.5A patent/EP3640259A1/en not_active Withdrawn
- 2010-07-12 BR BR112012000784-0A patent/BR112012000784A2/pt not_active Application Discontinuation
- 2010-07-12 RU RU2012104778/10A patent/RU2561459C2/ru active
- 2010-07-12 DK DK10733117.5T patent/DK2454275T3/en active
- 2010-07-12 KR KR1020197027795A patent/KR102344985B1/ko active Active
- 2010-07-12 ES ES10733117.5T patent/ES2643554T3/es active Active
- 2010-07-12 SI SI201031560T patent/SI2454275T1/sl unknown
- 2010-07-12 IN IN456DEN2012 patent/IN2012DN00456A/en unknown
- 2010-07-12 EP EP10733117.5A patent/EP2454275B1/en active Active
- 2010-07-12 HU HUE17180720A patent/HUE047362T2/hu unknown
- 2010-07-12 CN CN201610487340.0A patent/CN106117325B/zh active Active
- 2010-07-12 PL PL10733117T patent/PL2454275T3/pl unknown
- 2010-07-12 KR KR1020157018698A patent/KR101667174B1/ko active Active
- 2010-07-12 EP EP25220941.6A patent/EP4699614A2/en active Pending
- 2010-07-12 EP EP23194794.6A patent/EP4299070A3/en active Pending
- 2010-07-12 CN CN201080038953.7A patent/CN102482332B/zh active Active
- 2010-07-12 JP JP2012520707A patent/JP5887268B2/ja active Active
- 2010-07-12 PT PT171807209T patent/PT3252070T/pt unknown
- 2010-07-12 MX MX2012000615A patent/MX2012000615A/es active IP Right Grant
- 2010-07-12 EP EP22185200.7A patent/EP4141024A1/en not_active Withdrawn
- 2010-07-12 MX MX2016009206A patent/MX375629B/es unknown
- 2010-07-12 MX MX2014008854A patent/MX340718B/es unknown
-
2012
- 2012-01-05 US US13/344,399 patent/US8927229B2/en active Active
- 2012-01-05 US US13/344,420 patent/US8357541B2/en active Active
- 2012-01-12 MX MX2020009978A patent/MX2020009978A/es unknown
- 2012-02-28 US US13/407,662 patent/US8932827B2/en active Active
- 2012-05-10 US US13/468,889 patent/US8324349B2/en active Active
-
2014
- 2014-12-05 US US14/561,402 patent/US9206409B2/en active Active
-
2015
- 2015-10-30 JP JP2015214835A patent/JP6356651B2/ja active Active
- 2015-12-07 US US14/961,327 patent/US9719076B2/en active Active
-
2016
- 2016-11-10 JP JP2016219708A patent/JP6704329B2/ja active Active
-
2017
- 2017-07-31 US US15/664,456 patent/US10465178B2/en active Active
- 2017-10-11 CY CY20171101055T patent/CY1119519T1/el unknown
-
2019
- 2019-11-04 US US16/673,444 patent/US11124786B2/en active Active
- 2019-12-31 CY CY20191101367T patent/CY1122567T1/el unknown
-
2020
- 2020-01-09 JP JP2020001854A patent/JP2020078306A/ja not_active Withdrawn
-
2021
- 2021-06-07 US US17/340,720 patent/US11203748B2/en active Active
- 2021-09-01 JP JP2021142559A patent/JP2021193103A/ja active Pending
- 2021-10-19 US US17/505,537 patent/US11326155B2/en active Active
-
2022
- 2022-01-19 US US17/579,208 patent/US11525130B2/en active Active
- 2022-03-15 US US17/694,962 patent/US20220204958A1/en not_active Abandoned
- 2022-03-15 US US17/694,932 patent/US11518986B2/en active Active
- 2022-04-29 US US17/732,951 patent/US20220251532A1/en not_active Abandoned
- 2022-06-08 US US17/835,503 patent/US11530400B2/en active Active
- 2022-09-27 US US17/953,789 patent/US20230021648A1/en not_active Abandoned
- 2022-09-27 US US17/953,882 patent/US12241098B2/en active Active
- 2022-12-19 US US18/084,505 patent/US20230123158A1/en not_active Abandoned
-
2024
- 2024-06-19 JP JP2024098461A patent/JP2024111147A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532932A5 (https=) | ||
| RU2012104778A (ru) | Способ и система для получения ботулинического нейротоксина | |
| RU2015142657A (ru) | Интегрированное непрерывное производство терапевтических белковых лекарственных веществ | |
| CN101235394A (zh) | 一种分离提取富马酸的方法 | |
| CN104027797A (zh) | 一种白喉疫苗的制备方法 | |
| CN117512031A (zh) | 一种肺炎球菌荚膜多糖的纯化方法 | |
| CN116200433A (zh) | 一种冬虫夏草菌属真菌生物合成制备麦角硫因的方法 | |
| DE69106407T2 (de) | Verfahren zur Herstellung von rekombinantem menschlichem gamma-Interferon ohne Cystein und ohne Methionin am N-Terminal. | |
| CN101481403B (zh) | 一种酵母来源重组蛋白发酵液的双水相固液分离方法 | |
| CN103695325B (zh) | 一种热带假丝酵母及一种微生物法制备l-缬氨酸的方法 | |
| KR102903132B1 (ko) | 보툴리누스 독소의 제조 방법 | |
| CN117205129A (zh) | 高山火绒草类囊泡的提取方法及其在制备皮肤细胞胶原再生、修复产品中的应用 | |
| CN101372364B (zh) | 一种连续、批量纯化细菌磁小体的方法 | |
| CN113430146B (zh) | 表达石杉碱甲的苏云金芽孢杆菌hw1株及其应用 | |
| Jing et al. | High-efficiency flocculation of Leptosphaerulina australis J-22 to Chlorella vulgaris: Characteristics, optimal parameters and mechanisms | |
| CN113774004A (zh) | 一株短乳杆菌及循环利用其全细胞制备γ-氨基丁酸的方法 | |
| CN104531573B (zh) | 一种解淀粉芽孢杆菌及其应用 | |
| CN117776410B (zh) | 西洼湖戈登氏菌eps在降解增塑剂中的应用 | |
| CN102433289A (zh) | 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法 | |
| CN102433290B (zh) | 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法 | |
| CN103965275B (zh) | 一种链霉菌发酵代谢产物新奥霉素的分离提取方法 | |
| CN118006718A (zh) | 一种具有抗炎功能的活性肽组合物及其制备方法和应用 | |
| CN118755622A (zh) | 一种用于提取丝状蓝藻生物活性成分的方法及其应用 | |
| CN114341167A (zh) | 纯化肉毒杆菌毒素的方法 | |
| CN114409765B (zh) | 抗体的纯化方法 |